Alnylam and Sanofi announced a strategic restructuring of their RNAi therapeutics alliance to streamline and optimize development and commercialization of certain products for rare genetic diseases.
Biogen and Ionis Pharmaceuticals announced that they entered into a new collaboration agreement to identify new antisense oligonucleotide drug candidates for the treatment of spinal muscular atrophy (SMA).
Teva Pharmaceutical Industries Ltd. announced that the U.S. FDA approved Austedo (deutetrabenazine) tablets for the treatment of tardive dyskinesia in adults.
Boosts in R&D Spending Drive Biotech Innovation
21st Century Cures Act, Biologicals, Biotech, Diagnostics, Genetic Diseases, IDMP (Identification of Medicinal Products), Innovation, Investments, Medical Breakthroughs, Medicare Access and CHIP Authorization Act (MACRA), Nasdaq Biotech Index, R&D, Tufts Center for the Study of Drug DevelopmentFueled by a desire for innovation and new medical breakthroughs, the biotech industry continues to enjoy substantial growth due to increased investment in R&D.
X-Chem announced a collaboration with Vertex for the discovery of small-molecule leads against validated targets for severe, genetic diseases.
